News

Merck fulfills spin-off promise
Enlarge image

BusinessSwitzerlandGermany

Merck fulfills spin-off promise

01.08.2012 - Merck Serono has spun off the first company as part of its Entrepreneur Partnership Program. The project was launched in April 2012 when mother company Merck KGaA in Darmstadt had decided to end its activities in Geneva.

Newco Prexton Therapeutics will be formed around Merck Serono's R&D portfolio in the field of Parkinson's disease and will focus on programmes that target the metabotropic glutamate receptors mGluR3 and mGluR4. Prexton will be hosted in the offices and laboratory of Eclosion, a biotech start-up incubator supported by the Geneva authorities and Merck Serono which will invest €2.1m as seed funding. Helping spin-off companies such as Prexton was one of Merck Serono’s proposals to employee groups unsatisfied by social plan and severance options. In total, the pharma has reserved €30m to back start-ups by employees at its operations in Geneva. Prexton will be run by a team of Merck Serono scientists, with a member of Merck Serono Ventures on the board of directors.

http://www.european-biotechnology-news.com/news/news/2012-03/merck-fulfills-spin-off-promise.html

M&AIrelandUK

05.08.2015 Irish pharma and biotech major Shire wants to be number one in orphan diseases, and is setting out to acquire US-American Baxalta in a US$30bn deal – by any means necessary.

R&DUKSweden

04.08.2015 In a deal worth US$65m upfront, AstraZeneca is again teaming up with long-time partner Isis Pharmaceuticals Inc., this time to discover and develop RNA antisense drugs for cardiovascular, metabolic and renal diseases.

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • IMMUNICUM AB (S)33.00 SEK32.00%
  • ZEALAND PHARMA (DK)151.00 DKK4.86%
  • CYTOS (CH)0.46 CHF4.55%

FLOP

  • OREXO (S)53.25 SEK-28.76%
  • THERAMETRICS (CH)0.06 CHF-14.29%
  • ZELTIA (E)3.69 EUR-8.44%

TOP

  • CHRONTECH PHARMA (S)0.02 SEK100.0%
  • DBV TECHNOLOGIES (F)80.79 EUR53.2%
  • BIOTIE THERAPEUTICS (FI)0.22 EUR37.5%

FLOP

  • BIOTEST (D)26.60 EUR-61.7%
  • BIOTECH PHARMACON (N)9.30 NOK-46.9%
  • EVOCUTIS (UK)0.16 GBP-27.3%

TOP

  • ADOCIA (F)89.23 EUR535.1%
  • DBV TECHNOLOGIES (F)80.79 EUR324.1%
  • FORMYCON (D)28.54 EUR319.1%

FLOP

  • CHRONTECH PHARMA (S)0.02 SEK-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.50 SEK-72.0%
  • NEOVACS (F)1.04 EUR-69.7%

No liability assumed, Date: 04.08.2015